Several studies have demonstrated that estrogen performs favorable effects in MDD via modulating monoamine neurotransmitters (DA and 5-hydroxytryptamine), inflammatory processes, and dendritic spine number.[50,51] The activation of ERK and PI3K elevates after acute treatment with 17β-estradiol. This evidence concerns the gene MAPK1 and major depressive disorder.